These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 1942536)

  • 21. [Plasma exchange therapy in patients with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome].
    Ikeda Y; Kikuchi M
    Nihon Rinsho; 1992 Jan; 50 Suppl():293-7. PubMed ID: 1578694
    [No Abstract]   [Full Text] [Related]  

  • 22. The TITAN trial--assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura.
    Holz JB
    Transfus Apher Sci; 2012 Jun; 46(3):343-6. PubMed ID: 22475545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Thrombotic thrombocytopenic purpura--recent development of TTP study].
    Ito K
    Nihon Rinsho; 1993 Jan; 51(1):114-6. PubMed ID: 8381882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura.
    Yarranton H; Lawrie AS; Purdy G; Mackie IJ; Machin SJ
    Transfus Med; 2004 Feb; 14(1):39-44. PubMed ID: 15043592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.
    Tsai HM; Rice L; Sarode R; Chow TW; Moake JL
    Ann Intern Med; 2000 May; 132(10):794-9. PubMed ID: 10819702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders.
    Moore JC; Hayward CP; Warkentin TE; Kelton JG
    Blood; 2001 Sep; 98(6):1842-6. PubMed ID: 11535519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postoperative thrombotic thrombocytopenic purpura in an infant: case report and literature review.
    Schiller O; Ash S; Schonfeld T; Kadmon G; Nahum E; Yacobovich J; Tamary H; Davidovits M
    J Pediatr Surg; 2011 Apr; 46(4):764-766. PubMed ID: 21496552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: reconsideration of treatment with cryopoor plasma.
    Raife TJ; Friedman KD; Dwyre DM
    Transfusion; 2006 Jan; 46(1):74-9. PubMed ID: 16398733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Thrombotic-thrombocytopenic purpura (Moschcowitz syndrome)].
    Chemnitz J; Schulz A; Diehl V; Söhngen D
    Med Klin (Munich); 2001 Jun; 96(6):343-50. PubMed ID: 11450586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura.
    Moake JL; Byrnes JJ; Troll JH; Rudy CK; Hong SL; Weinstein MJ; Colannino NM
    Blood; 1985 May; 65(5):1232-6. PubMed ID: 3873262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombotic thrombocytopenia induced in dogs and pigs. The role of plasma and platelet vWF in animal models of thrombotic thrombocytopenic purpura.
    Sanders WE; Reddick RL; Nichols TC; Brinkhous KM; Read MS
    Arterioscler Thromb Vasc Biol; 1995 Jun; 15(6):793-800. PubMed ID: 7773736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abnormal platelet von Willebrand factor interaction in patients with TTP.
    Rock G; Tittley P; Taylor JR
    Am J Hematol; 1988 Mar; 27(3):179-83. PubMed ID: 3126651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombosis and von Willebrand Factor.
    Shahidi M
    Adv Exp Med Biol; 2017; 906():285-306. PubMed ID: 27628010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Hemostatic Conundrum of Thrombotic Thrombocytopenic Purpura: a Case Report.
    Pillay E; Louw S
    Clin Lab; 2019 Jun; 65(6):. PubMed ID: 31232040
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Tersteeg C; Roodt J; Van Rensburg WJ; Dekimpe C; Vandeputte N; Pareyn I; Vandenbulcke A; Plaimauer B; Lamprecht S; Deckmyn H; Lopez JA; De Meyer SF; Vanhoorelbeke K
    Blood; 2017 Feb; 129(8):1030-1038. PubMed ID: 28011677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between platelet aggregating factor and von Willebrand factor in thrombotic thrombocytopenic purpura.
    Murphy WG; Moore JC; Barr RD; Pai MK; Kelton JG
    Br J Haematol; 1987 Aug; 66(4):509-13. PubMed ID: 3499167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Histopathology of thrombotic thrombocytopenic purpura].
    Asada Y; Sumiyoshi A
    Nihon Rinsho; 1993 Jan; 51(1):159-62. PubMed ID: 8433511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significance of endothelial deposition of von Willebrand factor in thrombotic thrombocytopenic purpura: autopsy findings of a case complicated with systemic lupus erythematosus.
    Ono T; Kawaguchi K; Onaka H; Ueda S; Inui T; Nagai H; Matsuo T; Kuwahara T
    Nihon Jinzo Gakkai Shi; 1993 Jan; 35(1):79-82. PubMed ID: 8336404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.
    Hollifield AL; Arnall JR; Moore DC
    Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. von Willebrand factor abnormalities and endothelial cell perturbation in a patient with acute thrombotic thrombocytopenic purpura.
    Moake JL; Rudy CK; Troll JH; Weinstein MJ; Colannino NM; Hong SL; Koutcher JA; Melaragno AJ; Manner CE
    Am J Med Sci; 1986 Jan; 291(1):47-50. PubMed ID: 3079954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.